LSX World Congress

R&D

LSX2026: Non-opioid pain relief and pharma positivity, with ...

Mike Cooke, CEO of AmacaThera, spoke with pharmaphorum at the LSX World Congress, including about non-opioid pain relief.

R&D

Interview at LSX 2026 with Alexander Gebauer

LSX2026: On a therapeutic vision for ocular disease, with Al...

Alexander Gebauer, co-founder & executive chairman of Galimedix Therapeutics, discusses transforming treatment of major neurodegenerative eye diseases

Patients

Interview at LSX 2026 with Hans Schambye

LSX2026: On promise and patience, with Hans Schambye

At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.

Market Access

Political uncertainties, tariffs, funding crunch? LSX World ...

The weather was hot in London for this year’s LSX World Congress – but what was the atmosphere like at Europe’s leading partnering, strategy, and investment event?

LSX2026: Non-opioid pain relief and pharma positivity, with ...

LSX2026: On a therapeutic vision for ocular disease, with Al...

LSX2026: On promise and patience, with Hans Schambye

Political uncertainties, tariffs, funding crunch? LSX World ...

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

LSX World Congress

Editor's Picks